190 related articles for article (PubMed ID: 11148202)
21. Posttranslational regulation of I-Ed by affinity for CLIP.
Rinderknecht CH; Belmares MP; Catanzarite TL; Bankovich AJ; Holmes TH; Garcia KC; Nanda NK; Busch R; Kovats S; Mellins ED
J Immunol; 2007 Nov; 179(9):5907-15. PubMed ID: 17947664
[TBL] [Abstract][Full Text] [Related]
22. H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection.
Martin WD; Hicks GG; Mendiratta SK; Leva HI; Ruley HE; Van Kaer L
Cell; 1996 Feb; 84(4):543-50. PubMed ID: 8598041
[TBL] [Abstract][Full Text] [Related]
23. The functional role of class II-associated invariant chain peptide (CLIP) in its ability to variably modulate immune responses.
Chaturvedi P; Hengeveld R; Zechel MA; Lee-Chan E; Singh B
Int Immunol; 2000 Jun; 12(6):757-65. PubMed ID: 10837403
[TBL] [Abstract][Full Text] [Related]
24. Rapid CLIP dissociation from MHC II promotes an unusual antigen presentation pathway in autoimmunity.
Ito Y; Ashenberg O; Pyrdol J; Luoma AM; Rozenblatt-Rosen O; Hofree M; Christian E; Ferrari de Andrade L; Tay RE; Teyton L; Regev A; Dougan SK; Wucherpfennig KW
J Exp Med; 2018 Oct; 215(10):2617-2635. PubMed ID: 30185635
[TBL] [Abstract][Full Text] [Related]
25. Distinct peptide loading pathways for MHC class II molecules associated with alternative Ii chain isoforms.
Bikoff EK; Kenty G; Van Kaer L
J Immunol; 1998 Apr; 160(7):3101-10. PubMed ID: 9531264
[TBL] [Abstract][Full Text] [Related]
26. MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation.
Gregers TF; Fleckenstein B; Vartdal F; Roepstorff P; Bakke O; Sandlie I
Int Immunol; 2003 Nov; 15(11):1291-9. PubMed ID: 14565927
[TBL] [Abstract][Full Text] [Related]
27. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
28. Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules.
Katz JF; Stebbins C; Appella E; Sant AJ
J Exp Med; 1996 Nov; 184(5):1747-53. PubMed ID: 8920863
[TBL] [Abstract][Full Text] [Related]
29. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
Patil NS; Pashine A; Belmares MP; Liu W; Kaneshiro B; Rabinowitz J; McConnell H; Mellins ED
J Immunol; 2001 Dec; 167(12):7157-68. PubMed ID: 11739539
[TBL] [Abstract][Full Text] [Related]
30. Type 1 diabetes associated HLA-DQ2 and DQ8 molecules are relatively resistant to HLA-DM mediated release of invariant chain-derived CLIP peptides.
Zhou Z; Reyes-Vargas E; Escobar H; Rudd B; Rockwood AL; Delgado JC; He X; Jensen PE
Eur J Immunol; 2016 Apr; 46(4):834-45. PubMed ID: 26707565
[TBL] [Abstract][Full Text] [Related]
31. Unexpected reactivities of T cells selected by a single MHC-peptide ligand.
Singh N; Van Kaer L
J Immunol; 1999 Oct; 163(7):3583-91. PubMed ID: 10490950
[TBL] [Abstract][Full Text] [Related]
32. What to do with HLA-DO/H-2O two decades later?
Welsh R; Song N; Sadegh-Nasseri S
Immunogenetics; 2019 Mar; 71(3):189-196. PubMed ID: 30683973
[TBL] [Abstract][Full Text] [Related]
33. Impaired antigen presentation by murine I-Ad class II MHC molecules expressed in normal and HLA-DM-defective human B cell lines.
Weenink S; Averdunk H; Boston T; Boswarva V; Guery JC; Adorini L; Mellins E; McCluskey J; Gautam AM
Int Immunol; 1997 Jun; 9(6):889-96. PubMed ID: 9199972
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Abeta(b-/-), H2-DM(-), and CIITA(-/-) in second-set skin allograft rejection.
Felix NJ; de Serres S; Meyer AA; Ting JP
J Surg Res; 2002 Feb; 102(2):185-92. PubMed ID: 11796017
[TBL] [Abstract][Full Text] [Related]
35. Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules.
Bangia N; Watts TH
Int Immunol; 1995 Oct; 7(10):1585-91. PubMed ID: 8562503
[TBL] [Abstract][Full Text] [Related]
36. A study of complexes of class II invariant chain peptide: major histocompatibility complex class II molecules using a new complex-specific monoclonal antibody.
Eastman S; Deftos M; DeRoos PC; Hsu DH; Teyton L; Braunstein NS; Hackett CJ; Rudensky A
Eur J Immunol; 1996 Feb; 26(2):385-93. PubMed ID: 8617308
[TBL] [Abstract][Full Text] [Related]
37. The MHC class II-associated invariant chain: a molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells.
Bertolino P; Rabourdin-Combe C
Crit Rev Immunol; 1996; 16(4):359-79. PubMed ID: 8954255
[TBL] [Abstract][Full Text] [Related]
38. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
Ramachandra L; Kovats S; Eastman S; Rudensky AY
J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
[TBL] [Abstract][Full Text] [Related]
39. Relaxed DM requirements during class II peptide loading and CD4+ T cell maturation in BALB/c mice.
Bikoff EK; Wutz G; Kenty GA; Koonce CH; Robertson EJ
J Immunol; 2001 Apr; 166(8):5087-98. PubMed ID: 11290790
[TBL] [Abstract][Full Text] [Related]
40. Nonclassical MHC class II molecules.
Alfonso C; Karlsson L
Annu Rev Immunol; 2000; 18():113-42. PubMed ID: 10837054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
